SPY317.59+3.21 1.02%
DIA260.82+3.58 1.39%
IXIC10,617.44+69.69 0.66%

Guardant Health Launches Clinical-Genomic Platform

Represents a large-scale liquid biopsy dataset of advanced cancer patients REDWOOD CITY, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, addresses

Benzinga · -

Represents a large-scale liquid biopsy dataset of advanced cancer patients

REDWOOD CITY, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, addresses the challenges of developing new precision oncology medicines by unveiling the GuardantINFORM™  platform featuring an extensive clinical-genomic liquid biopsy dataset of advanced cancer patients.

The GuardantINFORM platform is intended to help accelerate research and development of the next generation of cancer therapeutics by offering biopharma partners an in-silico platform that combines de-identified longitudinal clinical information and genomic data collected from the Guardant360® liquid biopsy test —over 100,000 tests to date. This robust dataset offers real-world insights into anti-cancer therapy use in the clinic, tumor evolution, and treatment resistance throughout each patient’s treatment journey for many advanced solid tumor cancers including non-small cell lung, breast, colon, and prostate. The most notable applications for the GuardantINFORM platform include:

  • Targeted drug development: Identify, characterize, and prioritize cohorts of patients with biomarker-defined cancers and in need of treatment options for potential new drug development indications and label expansions.
     
  • Clinical trial optimization: Incorporate real-world clinical-genomic data into clinical trial design, control arm simulation, clinical operations activities, and clinical development decision-making.
     
  • Post-marketing studies: Conduct health outcomes and safety studies of on- and off-label use of marketed therapies using real-world market insights and estimates of progression-free and overall survival in biomarker-defined cancers.

“The GuardantINFORM platform represents an important milestone in our mission to conquer cancer with data, with liquid biopsy samples from more than 100,000 patients accumulated over the past five years,” said Helmy Eltoukhy, Guardant Health co-founder and CEO. “The richness of this clinical-genomic platform, combined with the complexity and diversity of all metastatic solid tumors, offers researchers more immediate access to real-world drug resistance and tumor evolution information which we believe will accelerate their development of novel therapeutics and new indications for patients.”

Recent data presented at the AACR Virtual Annual Meeting II quantify1 the robustness of the GuardantINFORM real-world clinical-genomic platform, and its potential to support drug development using circulating tumor DNA (ctDNA) as a valuable alternative to serial tissue testing. In a cohort of patients who underwent Guardant360 serial ctDNA testing, test results were linked to de-identified medical and pharmacy claims; a robust longitudinal view of the diagnoses, treatments, and clinical outcomes was accessible for the majority of patients.1 The availability of clinical-genomic information following systemic therapy confirms that this platform can serve as a valuable resource for precision oncology drug development researchers to evaluate drug resistance and tumor evolution in patients with advanced cancer in a real-world setting.